CoLucid Pharmaceuticals
Founded Year
2005Stage
Acq - P2P | AcquiredTotal Raised
$86.85MValuation
$0000About CoLucid Pharmaceuticals
CoLucid Pharmaceuticals (NASDAQ: CLCD) aims to advance drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's pipeline includes lasmiditan, a treatment for migraine headache. Lasmiditan is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies such as triptans. Lasmiditan is a member of a drug class called "ditans" and, unlike triptans, penetrates the central nervous system (CNS) and selectively targets receptors expressed in the trigeminal pathway. Lasmiditan does not interact with vasoconstrictor receptors on peripheral blood vessels which are activated by triptans.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
CoLucid Pharmaceuticals Patents
CoLucid Pharmaceuticals has filed 4 patents.
The 3 most popular patent topics include:
- Benzamides
- Fluoroarenes
- Piperidines
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
12/5/2017 | 7/6/2021 | Benzamides, Pyridines, Fluoroarenes, Piperidines, Glucocorticoids | Grant |
Application Date | 12/5/2017 |
|---|---|
Grant Date | 7/6/2021 |
Title | |
Related Topics | Benzamides, Pyridines, Fluoroarenes, Piperidines, Glucocorticoids |
Status | Grant |
Latest CoLucid Pharmaceuticals News
Aug 25, 2022
Ildong’s migraine drug patent blocks latecomer’s market entry 바로가기 기자명 Kim Chan-hyuk 닫기 Ildong Pharmaceutical successfully registered a patent on Reyvow Tab. (ingredient: lasmiditan hemisuccinate), a migraine treatment, blocking a possible market entry by a latecomer drugmaker. On Aug. 5, the Ministry of Food and Drug Safety (MFDS) put Ildong’s Reyvow Tab. 100mg and Reyvow Tab. 50mg on the list of patented medicines. The patent is about Reyvow’s pharmaceutical composition. Pharmaceutical’s new migraine treatment Reyvow has been listed as a patent drug. With the successful listing of the patented drug, Ildong holds an exclusive right to the composition of lasmiditan hemisuccinate until April 2, 2030. Ildong took the first step to block a latecomer’s attempt to develop a drug using the same ingredient. CoLucid Pharmaceuticals, a U.S. firm, developed Reyvow as a new migraine treatment. In 2013, Ildong and CoLucid signed an agreement to give Ildong the right to sell drugs in Korea exclusively. However, after Eil Lilly acquired CoLucid, Ildong’s agreement for the sales right of Reyvow applies to Eli Lilly. According to Ildong, lasmiditan is a selective serotonin (5-HT) 1F receptor agonist that lowers neuropeptide release and inhibits pain transmission pathways, including the trigeminal nerve. Existing migraine drugs in the triptan class were limitedly used for patients with cardiovascular diseases, but lasmiditan does not affect the cardiovascular system, Ildong said. Ildong is preparing to release Reyvow in Korea after scoring regulatory approval in May. In 2019, Lilly obtained FDA approval for Reyvow in the U.S. However, Ildong will have to get health insurance benefits for Reyvow to raise prescription sales. Although the Health Insurance Review and Assessment Service’s (HIRA) Drug Reimbursement Evaluation Committee recognized that Reyvow was eligible for reimbursement last month, Ildong did not accept the committee’s proposed reimbursement rate for Reyvow. Industry watchers said Lilly’s stance could have affected Ildong’s refusal. Ildong did not disclose any schedule for a market release of Reyvow. However, as Lilly is expected to win reimbursement for another migraine drug Emgality (galcanezumab), Ildong’s Reyvow will have to get insurance benefits to raise prescriptions. Attention is on whether Ildong will be able to speed up drug price negotiations for Reyvow, after winning the permit and passing the reimbursement review rapidly.
CoLucid Pharmaceuticals Frequently Asked Questions (FAQ)
When was CoLucid Pharmaceuticals founded?
CoLucid Pharmaceuticals was founded in 2005.
Where is CoLucid Pharmaceuticals's headquarters?
CoLucid Pharmaceuticals's headquarters is located at 2520 Meridian Parkway, Durham.
What is CoLucid Pharmaceuticals's latest funding round?
CoLucid Pharmaceuticals's latest funding round is Acq - P2P.
How much did CoLucid Pharmaceuticals raise?
CoLucid Pharmaceuticals raised a total of $86.85M.
Who are the investors of CoLucid Pharmaceuticals?
Investors of CoLucid Pharmaceuticals include Eli Lilly and Company, Domain Associates, Pappas Ventures, Triathlon Medical Venture Partners, Pearl Street Ventures and 8 more.
Who are CoLucid Pharmaceuticals's competitors?
Competitors of CoLucid Pharmaceuticals include Tetraphase Pharmaceuticals, Viamet Pharmaceuticals, Anacor Pharmaceuticals, Alexza Pharmaceuticals, Pozen and 11 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare CoLucid Pharmaceuticals to Competitors
Locus Pharmaceuticals is a privately held pharmaceutical company focused on developing small molecule therapeutic drugs to address unmet medical needs. The company's core technology is a fragment-based, computational approach, which Locus has combinated with highly integrated medicinal chemistry, crystallography and biology capabilities to create a unique drug design and development platform.
Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.
NeurAxon is discovering and developing next generation pain therapeutics focused on the inhibition of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization. NeurAxon's lead product candidate, NXN-188, is a first-in-class, dual-action small molecule incorporating both nNOS inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
is engaged in endocannabinoid research with the ability to address major unmet medical needs for selected diseases with clear competitive advantage over present therapies. The company's mission is the discovery, development and commercialization of therapeutics in the areas of neuropathic, inflammatory and somatic pain, obesity, neuroprotection, and addiction and glaucoma.
Ulysses Pharmaceuticals is dedicated to the discovery and development of safe antimicrobial agents for the treatment of severe and recurrent infections occurring in humans. The Company intends to become an industry leader in the antiinfective field through the development of new antibiotics including some acting as Trojan Horses that take advantage of essential microbial transport systems to specifically enter targeted pathogens. Ulysses concentrates on the development of advanced hit and lead compounds with promising features and characteristics that are indicative of potent antibacterial agents with potential for strong market penetration.
Ancora Pharmaceuticals aims to enable synthetic carbohydrate-based product discovery and development utilizing its carbohydrate synthesis capability, which is based on technology originally developed at the Massachusetts Institute of Technology (M.I.T.). The company is applying its synthesis technology both to internal drug development programs and strategic collaborations within the pharmaceutical and biotechnology sector.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
